Obesity Newcomer Metsera, Up 23%, Enters The Ring With A Punch The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Eli Lilly Rises 1.5% After Key Trading Signal A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Top S&P500 movers in Friday's session Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
